Skip to content
thestock.space

Indegene (INDGN) had a P/E of 35.9× on 6 Nov 2026, above the industry P/E of 26.0×. It earns ROCE of 15% and ROE of 13%, and sales and net profit grew 15% and 15% a year over 3 years. It has almost no debt, and its dividend yield is 0.4%. It is a small-cap company with a market cap of ₹14,684 Cr, ranked 3rd of 6 Health Information Services companies by market cap; the shares rose 14% over the past year.

As of 6 Nov 2026Prices are delayed about 15 minutes; fundamentals are from the quarter ended Sep 2026.How we calculate this

past year
Open
₹611.00
Day high
₹618.00
Day low
₹600.00
Prev. close
₹613.35
Volume
2.3 L

Health check

2 good · 1 fair · 3 to check
  • ReturnsAhead

    +13.8% over a year, better than 5 of 5 peers.

  • Price tagPricier

    P/E 35.9 vs industry 26.0.

  • GrowthSlow

    Sales +15.0%, profit +14.7% a year over 3 years.

  • ProfitabilityAverage

    ROCE 15.3% vs peer median 12.5%.

  • Balance sheetStretched

    Practically debt-free, Piotroski 3 of 9.

  • Red flagsNone found

    No warning signs in the headline numbers.

Compared with 5 industry peers. Computed from reported figures. Educational, not a recommendation.

Health Information Services

5 listed peers. Screen the industry

Small cap

₹14,684 Cr, #3 of 6 in its industry by size.

Defensive

Beta 0.68 vs the NIFTY 50: moves less than the market.

Key metrics

Last 12 months to Sep 2026: sales ₹4,131 Cr · profit ₹411 Cr
Market cap
₹14,684 Cr
Small cap
P/E
35.9
Industry 26.0
Price to book
4.37
Peers 1.98
Dividend yield
0.37%
ROE
13.2%
Peers 12.9%
ROCE
15.3%
Peers 12.5%
Debt to equity
0.05
Debt ₹157 Cr
EPS (TTM)
₹17.00
Face value ₹2
OPM (TTM)
16.5%
Net margin 10.0%
Sales growth
+39.6%
Latest quarter vs a year ago
Profit growth
+9.7%
Latest quarter vs a year ago
Price to sales
3.55
EV/EBITDA 20.8

Strengths and risks

Strengths

  • Practically debt-free.
  • Quarterly sales up 39.6% on a year ago.
  • Positive operating cash flow in each of the last 4 years.

No obvious red flags in the headline numbers.

Derived automatically from reported figures. Not a recommendation.

About Indegene

Indegene Limited operates as a digital-first life sciences commercialization company in India, the United States, Europe, North America, and internationally. It operates through Enterprise Medical Solutions, Enterprise Commercial Solutions, and Other segments. The company provides AI-embedded commercialization services for biopharmaceutical, emerging biotech, and medical devices companies. It also offers enterprise commercial, medical, and clinical…

Headquarters
Bengaluru
Employees
4,687
Sector
Healthcare
ISIN
INE065X01017
Website
indegene.com

Price range

52 weeks

₹414.00₹638.00

Today

₹600.00₹618.00
Avg volume (3M)
5.8 L
1-year return
plus 13.8%
From 52-week high
minus 4.4%

Analyst consensus

8 analysts
Strong buyMean target ₹696.63 plus 14.2%

Target range, with today’s price

Low ₹570.00High ₹790.00

Consensus from Yahoo Finance. Not a recommendation.

Peers · Health Information Services

Compare with peersScreen the whole industry
Company
IKSInventurus Knowledge Solutions1,657.10minus 5.70%27,79935.48.3229.6%28.2%33.7%45.7%33.2%0.00%plus 5.4%
SAGILITYSagility43.46minus 0.78%20,34519.81.9812.5%10.7%24.4%19.5%86.0%0.69%minus 15.1%
INDGNIndegene609.75minus 0.59%14,68435.94.3715.3%13.2%16.5%15.0%14.7%0.37%plus 13.8%
FABTECHFabtech Technologies131.98minus 1.78%58715.51.2111.8%12.9%2.4%28.3%20.8%0.45%minus 43.5%
TAKETAKE12.57plus 4.84%18632.26.1015.4%42.1%−0.9%−34.1%–0.00%minus 49.8%
DEEPAIDeep Health AI India1.640.00%2414.90.653.2%3.1%−457.4%−17.9%−3.4%12.20%minus 81.9%
Median of 5 peers–−0.78%58719.81.9812.5%12.9%2.4%19.5%27.0%0.45%−43.5%

Quarterly results

Consolidated, ₹ crore
SalesSelect a row below to chart it
₹ CrJun 25Dec 25Mar 26Jun 26Sep 26
7619421,0031,0631,122
606783840889937
155160164174186
20.4%16.9%16.3%16.4%16.5%
22.119.410.82915
3.74.67.26.46.9
21.639.641.844.146.4
––−20.3––
152135105153147
23.5%23.6%24.2%23.9%23.8%
11610379.7116112
4.824.263.304.814.64

Sep 25 not reported by the data source.

Profit & loss

Yearly, ₹ crore
Sales CAGR 3Y
+15.0%
Profit CAGR 3Y
+14.7%
EPS CAGR 3Y
+14.3%
ROE
13.2%
Net profitSelect a row below to chart it
₹ CrMar 2023Mar 2024Mar 2025Mar 2026
2,3062,5902,8393,511
–+12.3%+9.6%+23.6%
1,9102,0792,3052,886
396511534624
17.2%19.7%18.8%17.8%
58−45.959.233.3
31.346.319.416
59.876.180.2127
–11645.49.9
363459539525
26.7%26.6%24.6%23.6%
266337407401
–+26.5%+20.8%minus 1.4%
11.1214.0917.0216.62

Forecast

Your assumptions, not a prediction

Balance sheet

At each financial year end, ₹ crore
Total assetsSelect a row below to chart it
₹ CrMar 2023Mar 2024Mar 2025Mar 2026
44.344.447.948.1
1,0191,3852,5683,091
503490102144
6386276091,337
2,2042,5463,3264,620
152121139206
6.2–3.611.8
–10.7–57.1
7111,0171,6771,481
1,3351,3971,5072,864
2,2042,5463,3264,620

Cash flow

Yearly, ₹ crore
Cash from operationsSelect a row below to chart it
₹ CrMar 2023Mar 2024Mar 2025Mar 2026
130508442651
−893−327−683−512
333−66.2288−82.6
−43011446.755.8
−18.8−10.7−30−44.4
111497412606
–––−48

Shareholding pattern

Source: NSE filings

NSE hasn’t returned a shareholding pattern for this company. Institutions hold about 28.7% (Yahoo estimate).

Major shareholders

NSE filing

Filings & events

News

No recent news coverage found.

My notes

Private to you